anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study enrolls 13 patients with Type 2 Diabetes in Zhongshan Hospital who are on treatment with insulin. After screening for the inclusion and exclusion criteria, eligible patients will receive insulin dosage titration set by the Insulin Titration System Based on Deep Learning in the intervention trial. The goal of insulin therapy was to achieve preprandial capillary blood glucose between 5.6-7.8 mmol/L and postprandial capillary glucose less than 10.0mmol/L. All patients are studied for 5 consecutive days or untill hospital discharge. For each patient, capillary glucose concentration was measured at 7 time points of fasting, after breakfast, before and after lunch, before and after dinner, and before bedtime a day using Glucometer (Glupad, Sinomedisite, China). Capillary glucose measurements were performed by the nurse staff according to standard procedures with a point-of-care testing device, which is integrated into the HIS system. And continuous glucose monitoring (CGM) was performed using flash glucose monitoring (Abbott Freestyle Libre, USA) placed on the upper left arm. This study will be conducted in the Department of Endocrinology, Zhongshan Hospital,Fudan University.
This study examines hypertension control beyond the cascade of care framework, which assesses awareness, treatment, and control sequentially. The analysis included 52 434 hypertensive adults (blood pressure (BP) ≥140/90 mm Hg and/or treatment in the past 6 months), aged 25-69, from the French population-based CONSTANCES cohort from 2012 to 2021. The authors assessed the typical "awareness, treatment, and control" scenario and characterized other possible control patterns. The authors found that 13% achieved control. This percentage rose to 19% when considering individuals who were not aware but treated and controlled. This alternative control scenario was associated with female sex, younger age, higher education, Northern-African origin, and reporting prior cardiovascular diseases (CVD). Sub-Saharan African origin, diabetes and overweight/obesity were associated with the typical control scenario. This study highlights that applying a typical sequential cascade of care approach may lead to the exclusion of some specific groups of participants who do not fit into the defined categories.
There will be 2 follow-ups for each group. In the first follow-up for the experimental group, when symptoms begin on the first day of their menstrual period, they will be asked to fill out the Menstruation Symptom Scale and Visual Analogue Scale, and the designated music will be played for 30 minutes. After 30 minutes, he/she will be asked to fill out the same surveys again. In the 2nd follow-up (during the menstrual period one month after the first follow-up), they will be asked to repeat what was done in the 1st follow-up on the first day of their menstrual period.
This group will receive UsCare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
PROBLEM TO BE SOLVED: To obtain a medicinal plant composition effective despite being simple, useful for treating chronic constrictive pulmonary diseases, bronchitis and respiratory diseases by making the composition include respective ingredients extracted separately from specific plant materials. SOLUTION: This medicinal plant composition is obtained by including at least two ingredients separately extracted from specific plant materials, selected from among pref. 25 wt.% of Bryonia, pref. 25 wt.% of Ipecacuanha and pref. 25 wt.% of Drosera, and also pref. 25 wt.% of antimonyl potassium tartrate. Specifically, this composition is obtained by the following process: the above plant materials are washed so as to be free from dirt, the surface of the materials are sterilized with sodium hypochlorite, the resulting materials are dried, cut into chips which, in turn, are ground separately, and then subjected to separate extraction in a polar solvent such as acetone, the solvents are subsequently evaporated under a vacuum to afford respective powdery extracts, and at least two of the extracts is mixed with antimonyl potassium tartrate in the weight ratio of (100-75):(0-25).
BACKGROUND: Priapism induces regulation of Transforming Growth Factor-β1 (TGF-β1) expression and collagen-type-1 deposition. This will replace the normal corpora cavernosa with fibrotic tissue which eventually resulted in erectile dysfunction. It is also known that the fibrosis process of corpora cavernosa is related to Renin-Angiotensin II System (RAS). Angiotensin II receptor blockers (ARB), especially losartan, inhibit the inflammation process and fibrotic tissue formation. This study evaluated the effect of losartan in reducing fibrosis in priapism by evaluating TGF-β1 and collagen-type-1 in cavernous tissue and determined the effect of losartan in preventing fibrosis in priapism model of Wistar rats assessed by the metavir score.
METHODS: A total of eighteen male Wistar rats mean were divided into five groups. For the priapism models, we applied negative pressure on the penis to make an artificial erection to mimic the priapism process. The control groups were observed and the treatment groups were orally given losartan 15 mg/kg/day. Corpora cavernosa was harvested for TGF-β1 and collagen-type-1 measurement using an enzyme-linked immunosorbent assay (ELISA). The fibrotic tissue of each rat was then collected and assessed histopathologically with the metavir scoring system.
RESULTS: Penile TGF-β1 concentration in the losartan-treated group was not significantly different on day 10 and day 28 of observation (p10=0,30; p28=0,17). Meanwhile, collagen-type-1 concentration was significantly lower compared to control group (p10=0,002; p28=0,01). There was a significant difference in metavir scores in rats that received losartan and those who did not (p<0,05).
CONCLUSION: Losartan could suppress the fibrosis process in the priapism model. It could decrease the collagen type 1 deposition during corpora cavernosa tissue regeneration. Based on the metavir score, the group receiving losartan therapy was better than the control group.
An analytic method to evaluate performance of lactating animals by use of a parameterized algebraic model based on hypotheses about the physiology of lactation. Observed production data are fitted to the model to generate a set of parameter values which optimize compliance between model and data. Fitted parameter values summarize the lactation production of the animal or group. Inferences can be made from the fitted parameter values by referring to the physiologic assumptions made in deriving the model, and from their relationship with global or localized standards. Inferences can be used in managing health and productivity of the individual or group, for the development and testing of products which influence the health and productivity of lactating animals, and for evaluating genotype of animals or environmental conditions. Parameter values can be used recursively to improve the fitting process.
BACKGROUND: Despite the fact that the COVID-19 epidemic has already ended, there is no clear answer to the question - what is the nature of the imbalance in the hemocoagulation system, and which phenomena prevail - thrombosis or hemorrhage? More and more new works appear describing the occurrence of deep, extensive hematomas in patients with COVID-19. However, this experience requires further discussion and understanding.
CASE DESCRIPTION: From October 2020 to January 2021, 7 (2,1% among all hospitalized with COVID-19 in this period) patients with developed hematomas were observed at the COVID-19 hospital. All of them, taking into account their severe condition (according to the SOFA scale) and the high risk of thromboembolic complications (according to the Caprini scale), received a therapeutic dose of calcium nadroparin. Superficial hematomas were observed in 2 patients, and deep hematomas - in 5 patients. Their volume was up to 340 ml. Instrumental diagnostics included ultrasound and computed tomography. The most difficult were hematomas in the area of musculus iliopsoas. The median time of the onset of hematomas from the start of treatment was 7 days (interquartile range [IQR], 4-9 days). The indication for puncture was a hematoma volume of more than 100 ml, as well as a suspicion of suppuration. Analysis of coagulograms revealed signs of hypercoagulation and imbalance in the blood coagulation system. In 3 patients, the D-dimer level exceeded 4000 ng/ml. They were fatal, and autopsy revealed multiple thrombosis of the small branches of the pulmonary artery. Deep vein thrombosis of the lower extremities was not detected. The mortality rate among patients with developed hematomas was 42.9%, and the average mortality rate for this hospital in the indicated period of time was 7.1%.
CONCLUSIONS: An imbalance in which, along with thrombotic complications, hemorrhagic manifestations are observed, is one of the features of COVID-19. The deep hematomas developing at the same time are poorly understood and sharply complicate the course of the infection.
According to manufacturers' recommendations (Amgen: Neupogenᵀᴹ), filgrastim are to start 24 hrs after the last dose of chemotherapy and continue until absolute neutrophil count (ANC) has recovered to within the normal range (or for 14 days). However, for economic and practical reasons and/or patient's convenience, it has been common practice to initiate filgrastim at a later days of cycle and/or administer a shorter course of treatment. Data from several clinical studies have shown that 10-11 days' filgrastim treatment is required for optimal prophylaxis for febrile neutropenia (FN), and data from other cancers shows that suboptimal use of G-CSFs could deteriorate clinical outcomes. However, in two recent randomized study with breast cancer patients undergoing TAC chemotherapy, acceptable incidence (7-18%) of FN was shown with the consecutive 6 or 7-daily filgrastim schemes. Also, although there is theoretical concern that there can be wide fluctuations in the patient's ANC over time in alternate or intermittent filgrastim administration, because there was no difference in clinical outcomes between daily- or intermittent-dose filgrastim schedules in previous literatures, the intermittent every other day of 5 shot-filgrastim scheme would have clinical outcomes comparable with previous consecutive 6 or 7-daily filgrastim schemes in coverage of ANC nadir. Therefore, it can be justified to investigate the non-inferiority of intermittent every other days of 5 shot-filgrastim scheme compared with control arm using of pegfilgrastim on D2.
Anecdotal evidence from routine clinical care suggests that patients with sulphonylurea-treated KCNJ11 neonatal diabetes, when they eat, may experience mild hypoglycaemia if the food consumed lacks carbohydrate. It has been suggested that this may be due to regulation of insulin secretion via the incretin pathway as opposed to the classical ATP pathway. Therefore the investigators hypothesise that foods with a relatively high protein content compared to those with a relatively high carbohydrate content will result in excessive insulin secretion and relatively lower glucose values in KCNJ11 patients. This would be in contrast to healthy control subjects or subjects with SU-treated T2D where the insulin secretion will be moderated by the ambient glucose via the classical ATP pathway. The investigators will formally study this hypothesis by comparing the insulin, glucose and incretin hormone responses to a high protein meal with a high carbohydrate meal in people with KCNJ11 neonatal diabetes, people without diabetes and people with sulphonylurea-treated Type 2 Diabetes. To assess whether any effect seen is due to direct stimulation of the beta cell by the sulphonylurea itself, people with KCNJ11 neonatal diabetes will also undergo the same tests in the fasting state, having taken the sulphonylurea in the absence of any food.
The serious drawback underlying the biological annotation of whole-genome sequence data is the p >> n problem, which means that the number of polymorphic variants (p) is much larger than the number of available phenotypic records (n). We propose a way to circumvent the problem by combining a LASSO logistic regression with deep learning to classify cows as susceptible or resistant to mastitis, based on single nucleotide polymorphism (SNP) genotypes. Among several architectures, the one with 204,642 SNPs was selected as the best. This architecture was composed of two layers with, respectively, 7 and 46 units per layer implementing respective drop-out rates of 0.210 and 0.358. The classification of the test data resulted in AUC = 0.750, accuracy = 0.650, sensitivity = 0.600, and specificity = 0.700. Significant SNPs were selected based on the SHapley Additive exPlanation (SHAP). As a final result, one GO term related to the biological process and thirteen GO terms related to molecular function were significantly enriched in the gene set that corresponded to the significant SNPs. Our findings revealed that the optimal approach can correctly predict susceptibility or resistance status for approximately 65% of cows. Genes marked by the most significant SNPs are related to the immune response and protein synthesis.
INTRODUCTION AND HYPOTHESIS: Advances in our understanding of pelvic organ prolapse (POP) have been made with the introduction of valid, reliable measures of anatomy and patient-reported outcome measures.
METHODS: This review provides an overview of the evolution of POP measurement and its implications for clinical practice and research.
RESULTS: Since the introduction of the Pelvic Organ Prolapse Quantification (POPQ), studies have demonstrated that some degree of loss of anatomic support is normal, with as many as 40% of normal women having stage 2 prolapse. Vaginal support is dynamic and can wax and wane but is largely stable over time. Vaginal bulge symptoms are the most reliable and specific symptom for POP and the hymen is an important threshold for symptom development. Most pelvic floor symptoms have only weak to moderate correlation with the anatomic severity of POP. Treatment success rates are highly variable depending upon criteria used and definitions of anatomic success commonly used are too strict and often not clinically relevant. There is substantial discordance between subjective and anatomic measures of success, and both are dynamic, fluctuating between success and failure for many patients without intervening treatment.
CONCLUSIONS: Pelvic organ prolapse is multidimensional, dynamic, and has a complex impact on patients. Patients' symptoms are more clinically relevant than anatomic support. Symptomatic cure, particularly the absence of vaginal bulge symptoms, is more clinically relevant than anatomic cure and composite outcomes can be misleading and overestimate failure rates. Future studies should compare treatments using continuous variables along multiple dimensions rather than using composite outcomes or dichotomizing patients into success or failure.
N= 21 Blue-blocking goggles/screens from 6 p.m. to 08 a.m. in addition to treatment as usual (TAU). The goggles may be taken of when going to bed and turning of the light. For consenting patients who are unable to use goggles according to the protocol blue-blocking screens covering light-sources will be used.
Participants will attend an exercise class 3 days/week for 3 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant will be prescribed an individual walking prescription by the exercise leader, which will be adjusted accordingly, as each participant progresses throughout the 3 months. The exercise will be of moderate intensity. Alternate forms of aerobic exercise, such as but not limited to stationary bike, elliptical trainer, or treadmill walking, can be used in place of over-ground walking. This choice could be based on participant preference, the limitations of the exercise facility, or the participant's pain level.
Closely monitor cardiac function when ELLENCE is used in combination with other cardiotoxic agents. Patients receiving ELLENCE after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, may be at an increased risk of developing cardiotoxicity [see Dosage and Administration (2) and Warnings and Precautions (5.1)]. Trastuzumab may persist in the circulation for up to 7 months. Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. Monitor the patient's cardiac function closely if anthracyclines are used before this time. 

Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
BACKGROUND: Restless legs syndrome (RLS) is a neurological disorder that causes unpleasant symptoms in the legs when resting, which are relieved by movement. Pharmacotherapy is the standard treatment. However, current treatment provides only symptomatic relief and may result in adverse effects with long-term use. Treatment protocols using herbal medicines have emerged to compensate for this limitation.
CASE PRESENTATION: A 70-year-old Asian woman visited our hospital with worsening headaches that had persisted for 30 years. Her headaches were aggravated by night-time lower-extremity discomfort. The patient was diagnosed with RLS based on the 2012 Revised International Restless Leg Syndrome Study Group Diagnostic Criteria (IRIS). The patient was prescribed herbal medicines, Shihogyeji-tang, Gyejibokryeong-hwan, and Jakyakgamcho-tang, all of which contain Paeoniae Radix. Fourteen days after starting herbal medicine treatment, the IRIS score decreased from 30 to 18. The patient experienced less leg discomfort. Moreover, her sleep time increased, and her headaches resolved. After 28 days of herbal treatment, the IRIS score decreased to 9. Importantly, the patient reported no sleep disturbance or headaches. Subsequently, conventional medications were discontinued. The patient remained stable (IRIS score: 9-10). Herbal treatment was discontinued on day 163. At the last follow-up, (day 364), the patient has not reported any symptom recurrence.
CONCLUSIONS: We described a female patient with a 30-year history of RLS symptoms and related sleep disturbances that induced chronic uncontrolled headaches, who experienced improvements shortly after using herbal medicines containing Paeoniae Radix. Conventional medications were discontinued and the patient had no recurrence of symptoms. Considering these, herbal medicines containing Paeoniae Radix may be a suitable alternative treatment for RLS and its related symptoms.
Nutrition team will help patients implement an Atkins-type ketogenic diet. The diet should be continued for at least 6 weeks. They will be able to continue with the pharmacological-based treatment but without any changes having been made in the last 6 weeks or during the time they are in the study. To ensure adherence to the diet, urine ketones will be determined twice a week.
PURPOSE:To improve safety and stability by utilizing the salt of 2-(2-hydroxy-N- acyl-alkylamino)ethyl phosphoric ester expressed with a specified general formula as a forming agent for liposome. CONSTITUTION:The thin film of the salt of the ester mentioned below is formed by charging the salt of 2-(2-hydroxy-N-acyl-alkylamino)ethyl phosphoric ester expressed with the formula I (wherein, R1 and R2 express an alkyl group with normal or branching chain having 8-20C, M expresses Na ion, K ion, NH4 ion and tri-ethanolamine ion) and solvent, and then distilling off the solvent wit a rotary evaporator. Then a dispersion liq. of liposome is obtained by adding water and alternately treating with ultrasonic wave while heating on a water cooling of about 70 deg.C. The dispersion liq. is utilized as it is or after freeze-drying and pulverizing.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries, and is projected to become one of the foremost indications for liver transplantation (2). Both NAFLD and its most severe histopathologic subtype, non-alcoholic steatohepatitis (NASH) can progress to cirrhosis and its complications including hepatic malignancy, and are thus an important target for study. It is well-known that several risk factors are associated with the development of NAFLD, including obesity, type 2 diabetes mellitus, and metabolic syndrome (1), however their association with the presence and severity of histologic features of NAFLD/NASH has not been extensively examined. This study can help determine prognostic indicators for NALFD/NASH which can be useful in its prevention and treatment.

This is a retrospective chart review and de-identified data analysis. Data will be extracted from the patient database from the Methodist Liver Institute from April 2013 - June 2020. Patients with confirmed NAFLD/NASH via liver biopsy will be selected and NAFLD Activity Score and Fibrosis stage will be assessed. Data will then be collected on demographics, comorbid diseases, and medications from EPIC EMR system used by Methodist Health System.
Group 1, participants will perform a simple attention demanding task during No VR for 2 minutes, and with no VR again for another 2 minutes. They will also rate how distracted they were and how hard it was to concentrate during each 2 minute task.
ABSTRACT OF THE DISCLOSURE    A method of determining dTk isoenzyme levels of a human or animal body fluid or cell sample is disclosed herein.  The method includes the steps of reacting the sample with a substrate for the isoenzyme in the presence of a phosphate donor and a buffer system.  The amount of phosphorylated product formed is measured, that amount being proportional to the isoenzyme level.  The method uses (a) a buffer system at a pH ranging from 5 to 9 and which is present in a concentration of no more than 250 mM, (b) a substrate consisting of 2'-deoxy-5-halouridin, part of which has a radio-labelled 5-halogen, and which is present in a concen-tration ranging from 2 x 10-9 to 5 x 10-6M, and (c) the phosphate donor which is present in a concentration not exceeding 20 mM.  The sensitivity of the method permits measurement of minute amounts of dTk.  The method can be used for, e.g., the diagnosis, prognostics and monitoring of diseases involving altered ATP mediated dTk activity, e.g., cancers, tumours, and certain virus infections or altered CTP mediated dTk activity, e.g., HSV type 1, type 2, and VZV infections.